What does the future hold for biosimilars? How will the new administration, changing regulations and the recent FDA draft naming guidelines impact the industry?
On March 15th, The Atlantic hosts “The Next Drugs: The Future for Biosimilars – An Atlantic Policy Briefing,” an event underwritten by The Biosimilars Council, held at the Newseum in Washington, D.C. to discuss these topics and more.
The Policy Briefing will examine the biosimilar industry and educate healthcare industry professionals on planning for potential changes to the marketplace. Biosimilars have the unique ability to give patients much-needed access to lower-cost complex therapies, which ultimately impacts pharmaceutical companies, hospitals and physicians.
Panel One: Interchangeability and Naming Guidelines
- Jim Van Lieshout, Vice President, Market Access and Pharmacy Strategy, Apobiologix
- Len Lichtenfeld MD, Deputy Chief Medical Officer, American Cancer Society
Legal/Former FDA Expert:
- David Fox, Partner, Hogan Lovells
Panel Two: Biosimilars and the View from Washington
- Peter Welch
- Joie Chen, Journalist and Contributor, AtlanticLIVE
Interested in attending? Register now.
Conclusions from the Last Briefing
In December 2016, The Atlantic and The Biosimilars Council hosted “The Next Drugs: An Atlantic Policy Briefing on Biosimilars.” This event brought together more than 130 influencers and evaluated the beginning world of biosimilar medication and the regulatory framework that came with it. From this briefing, three conclusions were clear:
- Experts will need more biosimilars education
- Manufacturers will benefit from more regulatory clarity
- Everyone will benefit from biosimilar savings
Read our wrap up from the last biosimilars policy briefing or watch the event video from "Welcome to The Next Drugs: An Atlantic Policy Briefing."